Brent E. Silvers, M.D.; Decision and Order, 42014-42016 [2019-17622]
Download as PDF
khammond on DSKBBV9HB2PROD with NOTICES
42014
Federal Register / Vol. 84, No. 159 / Friday, August 16, 2019 / Notices
in the . . . dispensing of controlled
substances.’’ With respect to a
practitioner, the DEA has also long held
that the possession of authority to
dispense controlled substances under
the laws of the State in which a
practitioner engages in professional
practice is a fundamental condition for
obtaining and maintaining a
practitioner’s registration. See, e.g.,
James L. Hooper, M.D., 76 FR 71,371
(2011), pet. for rev. denied, 481 Fed.
Appx. 826 (4th Cir. 2012); Frederick
Marsh Blanton, M.D., 43 FR 27,616,
27,617 (1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . ., to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess State authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the State in which he practices. See,
e.g., Hooper, supra, 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Blanton, supra, 43 FR at 27,617.
The Georgia Controlled Substances
Act requires that ‘‘every person who
manufactures, distributes, or dispenses
any controlled substances within this
state or who proposes to engage in the
manufacture, distribution, or dispensing
of any controlled substance within this
state must obtain annually a registration
issued by the State Board of Pharmacy
in accordance with its rules.’’ Ga. Code
Ann. § 16–13–35(a) (West 1982). The
Act exempts from separate controlled
substance registration requirements,
‘‘persons licensed as a physician,
dentist, or veterinarian under the laws
of the state to use, mix, prepare,
dispense, prescribe, and administer
drugs in connection with medical
treatment to the extent provided by the
laws of this state.’’ Id. at 16–13–35(g)(2).
VerDate Sep<11>2014
16:10 Aug 15, 2019
Jkt 247001
According to the Medical Practice Act
of the State of Georgia, the definition of
a ‘‘physician’’ is a ‘‘person licensed to
practice medicine under this article,’’
and the definition of ‘‘to practice
medicine’’ is ‘‘to hold oneself out to the
public as being engaged in the diagnosis
or treatment of disease, defects, or
injuries of human beings; or the
suggestion, recommendation, or
prescribing of any form of treatment for
the intended palliation, relief, or cure of
any physical, mental, or functional
ailment or defect of any person.’’ Ga.
Code Ann. §§ 43–34–21(2), (3) (West
1981).
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice medicine in
Georgia. As already discussed, a person
must be registered to dispense a
controlled substance in Georgia, unless
he is licensed as a physician. Thus,
because Registrant is no longer a
licensed physician in Georgia and,
therefore, is no longer registered to or
authorized to dispense controlled
substances in Georgia, I will order that
Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FU2662523 issued to
Peter John Ulbrich, M.D. This Order is
effective September 16, 2019.
Dated: August 2, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019–17621 Filed 8–15–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Brent E. Silvers, M.D.; Decision and
Order
On May 9, 2019, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause to Brent E. Silvers, M.D.
(hereinafter, Registrant) of Irvine,
California. Order to Show Cause
(hereinafter, OSC), at 1. The OSC
proposed the revocation of Registrant’s
Certificate of Registration No.
BS2811392 on the ground that
Registrant ‘‘is without authority to
handle controlled substances in the
State of California, the state in which
[Registrant is] registered with the DEA.’’
Id. at 1–2 (citing 21 U.S.C. 824(a)(3)).
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Specifically, the OSC alleged that on
January 11, 2019, the Medical Board of
California (hereinafter, Board) issued a
Decision revoking Registrant’s
California medical license, effective
February 8, 2019. Id.
The OSC notified Registrant of the
right to request a hearing on the
allegations or to submit a written
statement while waiving the right to a
hearing, the procedures for electing each
option, and the consequences for failing
to elect either option. Id., at 2 (citing 21
CFR 1301.43). The OSC also notified
Registrant of the opportunity to submit
a corrective action plan. Id. at 2–3
(citing 21 U.S.C. 824(c)(2)(C)).
Adequacy of Service
In a Declaration dated June 19, 2019,
a Diversion Investigator (hereinafter, DI)
assigned to the Riverside District office,
Los Angeles Field Division, stated that
he and another DI traveled to
Registrant’s registered address located at
2 Hughes, Suite 150, Irvine, California
92618 on May 10, 2019. Request for
Final Agency Action dated July 10, 2019
(hereinafter, RFAA), Government
Exhibit (hereinafter, GX) GX 4 (DI’s
Declaration). The DI stated that upon
arrival at the registered address,
‘‘Registrant identified himself . . . as Dr.
Silvers’’ to the DIs. Id. The DI then
‘‘personally served the [OSC] on
Registrant by handing it to him.’’.
Registrant signed a DEA Form 12,
Receipt for Cash or Other Items, to
acknowledge his receipt of the Show
Cause Order. Id.; see also GX 4B.
In its RFAA, the Government
represents that ‘‘at least [thirty] days
have passed since the time the [OSC]
was served on Registrant’’ and he ‘‘has
not requested a hearing and has not
otherwise corresponded or
communicated with DEA.’’ RFAA, at 1.
The Government requests that
‘‘Registrant’s DEA Registration [ ] be
revoked based on 21 U.S.C. 824(a)(3)
because Registrant has no valid medical
license in California . . . [and] is
without state authority to handle
controlled substances in California.’’ Id.
at 2–3.
Based on the DI’s Declaration, the
Government’s written representations,
and my review of the record, I find that
the Government accomplished service
of the OSC on Registrant on May 10,
2019. I also find that more than thirty
days have now passed since the
Government accomplished service of
the OSC. Further, based on the
Government’s written representations, I
find that neither Registrant, nor anyone
purporting to represent the Registrant,
requested a hearing, submitted a written
statement while waiving Registrant’s
E:\FR\FM\16AUN1.SGM
16AUN1
Federal Register / Vol. 84, No. 159 / Friday, August 16, 2019 / Notices
right to a hearing, or submitted a
corrective action plan. Accordingly, I
find that Registrant has waived the right
to a hearing and the right to submit a
written statement and corrective action
plan. 21 CFR 1301.43(d) and 21 U.S.C.
824(c)(2)(C). I, therefore, issue this
Decision and Order based on the record
submitted by the Government, which
constitutes the entire record before me.
21 CFR 1301.43(e).
Findings of Fact
Registrant’s DEA Registration
Registrant is the holder of DEA
Certificate of Registration No.
BS2811392 at the registered address of
2 Hughes, Suite 150, Irvine, California
92618. GX 1 (Certification of
Registration Status). Pursuant to this
registration, Registrant is authorized to
dispense controlled substances in
schedules II through V as a practitioner.
Id. Registrant’s registration expires on
February 28, 2021, and is ‘‘in an active
pending status.’’ Id.
khammond on DSKBBV9HB2PROD with NOTICES
The Status of Registrant’s State License
On January 11, 2019, the Medical
Board of California (hereinafter, Board)
issued a Decision and Order
(hereinafter, Order) revoking
Registrant’s medical license, effective
February 8, 2019. GX 3 (Order). The
Board’s Order adopted the Proposed
Decision of a state Administrative Law
Judge (ALJ) following a lengthy hearing
resulting from Accusations brought by
the Board against Registrant. GX 3 (ALJ
Proposed Decision), at 1. According to
the ALJ’s Proposed Decision, the Board
initiated an investigation into
Registrant’s medical practice after
receiving anonymous complaints in
February and March 2016 and a
consumer complaint in July 2017,
which was accompanied by a copy of a
Complaint for Medical Negligence filed
in the Superior Court of California. Id.
at 2. On September 26, 2017, the Board
issued an ‘‘Interim Suspension Order
No Practice’’ against Registrant, which
was upheld on October 27, 2017. Id. On
April 26, 2018, the Board filed its First
Amended Accusation against Registrant
and it filed its Second Amended
Accusation on November 16, 2018. Id.
The ALJ affirmed the Board’s Second
Amended Accusation on December 28,
2018, and issued the Proposed Decision
revoking Registrant’s California
Physician’s and Surgeon’s Certificate.
Id. at 17.
The ALJ found that Registrant ‘‘has
complied with the terms of the Interim
Suspension Order and he has tested
negative for alcohol in random testing.’’
Id. at 2. However, the ALJ ultimately
VerDate Sep<11>2014
16:10 Aug 15, 2019
Jkt 247001
found that ‘‘clear and convincing
evidence established that [Registrant]
has a mild cognitive disorder and severe
alcohol use disorder,’’ which ‘‘is
adversely affecting [his] memory and
judgment’’ and that his ‘‘ability to
practice medicine safely is impaired
because a mental or physical illness [is]
affecting his competency.’’ Id. at 13. He
further found that ‘‘clear and convincing
evidence’’ established that Registrant
engaged in ‘‘unprofessional conduct
based on gross negligence or repeated
acts of negligence’’ and ‘‘unprofessional
conduct by engaging in acts of sexual
misconduct.’’ Id. at 14, 15. He
concluded that ‘‘[p]ublic protection is
best served by revocation of
[Registrant’s] license.’’ Id. at 17. The
Board adopted the ALJ’s Proposed
Decision and ordered that revocation
become effective on February 8, 2019.
GX 3 (Order).
According to the website of the
California Department of Consumer
Affairs, of which I take official notice,
Registrant’s license is still
revoked.1 https://search.dca.ca.gov/
details/8002/A/49201/cdbaeea6d15
fdfd3a0d8a46e76dde3f9 (last visited
July 19, 2019).
Accordingly, I find that Registrant
currently is not licensed to engage in the
practice of medicine in California, the
State in which he is registered with the
DEA.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of the Controlled
Substances Act (hereinafter, CSA),
‘‘upon a finding that the registrant . . .
has had his State license or registration
suspended . . . [or] revoked . . . by
competent State authority and is no
longer authorized by State law to engage
in the . . . dispensing of controlled
substances.’’ With respect to a
practitioner, the DEA has also long held
that the possession of authority to
1 Under the Administrative Procedure Act, an
agency ‘‘may take official notice of facts at any stage
in a proceeding—even in the final decision.’’
United States Department of Justice, Attorney
General’s Manual on the Administrative Procedure
Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint
1979). Pursuant to 5 U.S.C. 556(e), ‘‘[w]hen an
agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a
party is entitled, on timely request, to an
opportunity to show the contrary.’’ Accordingly,
Registrant may dispute my finding by filing a
properly supported motion for reconsideration
within 15 calendar days of the date of this Order.
Any such motion shall be filed with the Office of
the Administrator and a copy shall be served on the
Government. In the event Registrant files a motion,
the Government shall have 15 calendar days to file
a response.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
42015
dispense controlled substances under
the laws of the State in which a
practitioner engages in professional
practice is a fundamental condition for
obtaining and maintaining a
practitioner’s registration. See, e.g.,
James L. Hooper, M.D., 76 FR 71,371
(2011), pet. for rev. denied, 481 Fed.
Appx. 826 (4th Cir. 2012); Frederick
Marsh Blanton, M.D., 43 FR 27,616,
27,617 (1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . ., to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess State authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the State in which he practices. See,
e.g., Hooper, supra, 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Blanton, supra, 43 FR at 27,617.
According to the California Uniform
Controlled Substances Act, ‘‘No person
other than a physician . . . shall write
or issue a prescription.’’ Cal. Health &
Safety Code § 11150 (West, Westlaw
current with urgency legislation through
Ch. 5 of 2019 Reg. Sess.). Further,
‘‘physician,’’ as defined by California
statute, is a person who is ‘‘licensed to
practice’’ in California. Cal. Health &
Safety Code § 11024 (West, Westlaw
current with urgency legislation through
Ch. 5 of 2019 Reg. Sess.).
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice medicine in
California. As already discussed, a
physician must be a licensed
practitioner to dispense a controlled
substance in California. Thus, because
Registrant lacks authority to practice
medicine in California and, therefore, is
not authorized to handle controlled
substances in California, I will order
E:\FR\FM\16AUN1.SGM
16AUN1
42016
Federal Register / Vol. 84, No. 159 / Friday, August 16, 2019 / Notices
that Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. BS2811392 issued to
Brent E. Silvers, M.D. Further, I hereby
deny any pending application of Brent
E. Silvers, M.D. to renew or modify this
registration, as well as any pending
application of Brent E. Silvers, M.D. for
registration in California. This Order is
effective September 16, 2019.
Dated: August 2, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019–17622 Filed 8–15–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Federal Bureau of Investigation
[OMB Number 1110-New]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; New
Collection; Background Investigation
Medical Release Forms
Federal Bureau of
Investigation, Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Department of Justice,
Federal Bureau of Investigation, is
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: The Department of Justice
encourages public comment and will
accept input until September 16, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gabrielle Fournet, Unit Chief, Federal
Bureau of Investigation, 935
Pennsylvania Avenue NW, Washington,
DC, HQ-Div11-OGA1@FBI.gov, 202–
651–2906.
Written comments and/or suggestions
can also be sent to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503 or sent
to OIRA_submissions@omb.eop.gov.
khammond on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:10 Aug 15, 2019
Jkt 247001
Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
➢ Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Federal Bureau of
Investigation, including whether the
information will have practical utility;
➢ Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
➢ Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
➢ Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
SUPPLEMENTARY INFORMATION:
Overview of This Information
Collection
1. Type of Information Collection:
New Collection.
2. The Title of the Form/Collection:
Background Investigation Medical
Release Forms.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
FD–1152 and FD–1153. The applicable
component within the Department of
Justice is the Federal Bureau of
Investigation.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: This form is needed for
obtaining medical information for non
FBI personnel, for which the FBI has
been requested to obtain medical release
information. For instance, when the FBI
has been requested to conduct
background investigations on non-FBI
employees applying for positions with
other government agencies, sometimes
medical information must be obtained.
When it occurs, the non-FBI employee
applying for the position is asked to
complete the medical release form so
the FBI has the authority to seek the
medical information.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that not more
than 50 people would need to complete
this form in a year. It should only take
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
each person about 15 minutes to
complete the form.
6. An estimate of the total public
burden (in hours) associated with the
collection: There is an estimated 12.5
total annual burden hours associated
with this collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405A,
Washington, DC 20530.
Dated: August 13, 2019.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2019–17613 Filed 8–15–19; 8:45 am]
BILLING CODE 4410–02–P
DEPARTMENT OF JUSTICE
[CPCLO Order No. 004–2019]
Privacy Act of 1974; Systems of
Records
Executive Office for
Immigration Review, United States
Department of Justice.
ACTION: Notice of a new system of
records.
AGENCY:
Pursuant to the Privacy Act of
1974, and Office of Management and
Budget (OMB) Circular No. A–108,
notice is hereby given that the Executive
Office for Immigration Review (EOIR), a
component within the United States
Department of Justice (DOJ or
Department), proposes to develop a new
system of records titled Office of the
Chief Administrative Hearing Officer
(OCAHO) Case Management System
(CMS), JUSTICE/EOIR–002. The EOIR
proposes to establish this system of
records to track and manage case
information and documents for OCAHO
cases. The system provides an electronic
platform to track cases and
electronically maintain records
previously maintained in paper form for
the purpose of more efficiently
managing these records and providing
better access to the records for parties to
the proceedings.
DATES: In accordance with 5 U.S.C.
552a(e)(4) and (11), this system of
records will begin operation on the
publication date, subject to a 30-day
period in which to comment on the
routine uses, described below. Please
submit any comments by September 16,
2019.
ADDRESSES: The public, OMB, and
Congress are invited to submit any
SUMMARY:
E:\FR\FM\16AUN1.SGM
16AUN1
Agencies
[Federal Register Volume 84, Number 159 (Friday, August 16, 2019)]
[Notices]
[Pages 42014-42016]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17622]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Brent E. Silvers, M.D.; Decision and Order
On May 9, 2019, the Assistant Administrator, Diversion Control
Division, Drug Enforcement Administration (hereinafter, DEA or
Government), issued an Order to Show Cause to Brent E. Silvers, M.D.
(hereinafter, Registrant) of Irvine, California. Order to Show Cause
(hereinafter, OSC), at 1. The OSC proposed the revocation of
Registrant's Certificate of Registration No. BS2811392 on the ground
that Registrant ``is without authority to handle controlled substances
in the State of California, the state in which [Registrant is]
registered with the DEA.'' Id. at 1-2 (citing 21 U.S.C. 824(a)(3)).
Specifically, the OSC alleged that on January 11, 2019, the Medical
Board of California (hereinafter, Board) issued a Decision revoking
Registrant's California medical license, effective February 8, 2019.
Id.
The OSC notified Registrant of the right to request a hearing on
the allegations or to submit a written statement while waiving the
right to a hearing, the procedures for electing each option, and the
consequences for failing to elect either option. Id., at 2 (citing 21
CFR 1301.43). The OSC also notified Registrant of the opportunity to
submit a corrective action plan. Id. at 2-3 (citing 21 U.S.C.
824(c)(2)(C)).
Adequacy of Service
In a Declaration dated June 19, 2019, a Diversion Investigator
(hereinafter, DI) assigned to the Riverside District office, Los
Angeles Field Division, stated that he and another DI traveled to
Registrant's registered address located at 2 Hughes, Suite 150, Irvine,
California 92618 on May 10, 2019. Request for Final Agency Action dated
July 10, 2019 (hereinafter, RFAA), Government Exhibit (hereinafter, GX)
GX 4 (DI's Declaration). The DI stated that upon arrival at the
registered address, ``Registrant identified himself . . . as Dr.
Silvers'' to the DIs. Id. The DI then ``personally served the [OSC] on
Registrant by handing it to him.''. Registrant signed a DEA Form 12,
Receipt for Cash or Other Items, to acknowledge his receipt of the Show
Cause Order. Id.; see also GX 4B.
In its RFAA, the Government represents that ``at least [thirty]
days have passed since the time the [OSC] was served on Registrant''
and he ``has not requested a hearing and has not otherwise corresponded
or communicated with DEA.'' RFAA, at 1. The Government requests that
``Registrant's DEA Registration [ ] be revoked based on 21 U.S.C.
824(a)(3) because Registrant has no valid medical license in California
. . . [and] is without state authority to handle controlled substances
in California.'' Id. at 2-3.
Based on the DI's Declaration, the Government's written
representations, and my review of the record, I find that the
Government accomplished service of the OSC on Registrant on May 10,
2019. I also find that more than thirty days have now passed since the
Government accomplished service of the OSC. Further, based on the
Government's written representations, I find that neither Registrant,
nor anyone purporting to represent the Registrant, requested a hearing,
submitted a written statement while waiving Registrant's
[[Page 42015]]
right to a hearing, or submitted a corrective action plan. Accordingly,
I find that Registrant has waived the right to a hearing and the right
to submit a written statement and corrective action plan. 21 CFR
1301.43(d) and 21 U.S.C. 824(c)(2)(C). I, therefore, issue this
Decision and Order based on the record submitted by the Government,
which constitutes the entire record before me. 21 CFR 1301.43(e).
Findings of Fact
Registrant's DEA Registration
Registrant is the holder of DEA Certificate of Registration No.
BS2811392 at the registered address of 2 Hughes, Suite 150, Irvine,
California 92618. GX 1 (Certification of Registration Status). Pursuant
to this registration, Registrant is authorized to dispense controlled
substances in schedules II through V as a practitioner. Id.
Registrant's registration expires on February 28, 2021, and is ``in an
active pending status.'' Id.
The Status of Registrant's State License
On January 11, 2019, the Medical Board of California (hereinafter,
Board) issued a Decision and Order (hereinafter, Order) revoking
Registrant's medical license, effective February 8, 2019. GX 3 (Order).
The Board's Order adopted the Proposed Decision of a state
Administrative Law Judge (ALJ) following a lengthy hearing resulting
from Accusations brought by the Board against Registrant. GX 3 (ALJ
Proposed Decision), at 1. According to the ALJ's Proposed Decision, the
Board initiated an investigation into Registrant's medical practice
after receiving anonymous complaints in February and March 2016 and a
consumer complaint in July 2017, which was accompanied by a copy of a
Complaint for Medical Negligence filed in the Superior Court of
California. Id. at 2. On September 26, 2017, the Board issued an
``Interim Suspension Order No Practice'' against Registrant, which was
upheld on October 27, 2017. Id. On April 26, 2018, the Board filed its
First Amended Accusation against Registrant and it filed its Second
Amended Accusation on November 16, 2018. Id. The ALJ affirmed the
Board's Second Amended Accusation on December 28, 2018, and issued the
Proposed Decision revoking Registrant's California Physician's and
Surgeon's Certificate. Id. at 17.
The ALJ found that Registrant ``has complied with the terms of the
Interim Suspension Order and he has tested negative for alcohol in
random testing.'' Id. at 2. However, the ALJ ultimately found that
``clear and convincing evidence established that [Registrant] has a
mild cognitive disorder and severe alcohol use disorder,'' which ``is
adversely affecting [his] memory and judgment'' and that his ``ability
to practice medicine safely is impaired because a mental or physical
illness [is] affecting his competency.'' Id. at 13. He further found
that ``clear and convincing evidence'' established that Registrant
engaged in ``unprofessional conduct based on gross negligence or
repeated acts of negligence'' and ``unprofessional conduct by engaging
in acts of sexual misconduct.'' Id. at 14, 15. He concluded that
``[p]ublic protection is best served by revocation of [Registrant's]
license.'' Id. at 17. The Board adopted the ALJ's Proposed Decision and
ordered that revocation become effective on February 8, 2019. GX 3
(Order).
According to the website of the California Department of Consumer
Affairs, of which I take official notice, Registrant's license is still
revoked.\1\ https://search.dca.ca.gov/details/8002/A/49201/cdbaeea6d15fdfd3a0d8a46e76dde3f9 (last visited July 19, 2019).
---------------------------------------------------------------------------
\1\ Under the Administrative Procedure Act, an agency ``may take
official notice of facts at any stage in a proceeding--even in the
final decision.'' United States Department of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e),
``[w]hen an agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a party is
entitled, on timely request, to an opportunity to show the
contrary.'' Accordingly, Registrant may dispute my finding by filing
a properly supported motion for reconsideration within 15 calendar
days of the date of this Order. Any such motion shall be filed with
the Office of the Administrator and a copy shall be served on the
Government. In the event Registrant files a motion, the Government
shall have 15 calendar days to file a response.
---------------------------------------------------------------------------
Accordingly, I find that Registrant currently is not licensed to
engage in the practice of medicine in California, the State in which he
is registered with the DEA.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of the
Controlled Substances Act (hereinafter, CSA), ``upon a finding that the
registrant . . . has had his State license or registration suspended .
. . [or] revoked . . . by competent State authority and is no longer
authorized by State law to engage in the . . . dispensing of controlled
substances.'' With respect to a practitioner, the DEA has also long
held that the possession of authority to dispense controlled substances
under the laws of the State in which a practitioner engages in
professional practice is a fundamental condition for obtaining and
maintaining a practitioner's registration. See, e.g., James L. Hooper,
M.D., 76 FR 71,371 (2011), pet. for rev. denied, 481 Fed. Appx. 826
(4th Cir. 2012); Frederick Marsh Blanton, M.D., 43 FR 27,616, 27,617
(1978).
This rule derives from the text of two provisions of the CSA.
First, Congress defined the term ``practitioner'' to mean ``a physician
. . . or other person licensed, registered, or otherwise permitted, by
. . . the jurisdiction in which he practices . . ., to distribute,
dispense, . . . [or] administer . . . a controlled substance in the
course of professional practice.'' 21 U.S.C. 802(21). Second, in
setting the requirements for obtaining a practitioner's registration,
Congress directed that ``[t]he Attorney General shall register
practitioners . . . if the applicant is authorized to dispense . . .
controlled substances under the laws of the State in which he
practices.'' 21 U.S.C. 823(f). Because Congress has clearly mandated
that a practitioner possess State authority in order to be deemed a
practitioner under the CSA, the DEA has held repeatedly that revocation
of a practitioner's registration is the appropriate sanction whenever
he is no longer authorized to dispense controlled substances under the
laws of the State in which he practices. See, e.g., Hooper, supra, 76
FR at 71,371-72; Sheran Arden Yeates, M.D., 71 FR 39,130, 39,131
(2006); Dominick A. Ricci, M.D., 58 FR 51,104, 51,105 (1993); Bobby
Watts, M.D., 53 FR 11,919, 11,920 (1988); Blanton, supra, 43 FR at
27,617.
According to the California Uniform Controlled Substances Act, ``No
person other than a physician . . . shall write or issue a
prescription.'' Cal. Health & Safety Code Sec. 11150 (West, Westlaw
current with urgency legislation through Ch. 5 of 2019 Reg. Sess.).
Further, ``physician,'' as defined by California statute, is a person
who is ``licensed to practice'' in California. Cal. Health & Safety
Code Sec. 11024 (West, Westlaw current with urgency legislation
through Ch. 5 of 2019 Reg. Sess.).
Here, the undisputed evidence in the record is that Registrant
currently lacks authority to practice medicine in California. As
already discussed, a physician must be a licensed practitioner to
dispense a controlled substance in California. Thus, because Registrant
lacks authority to practice medicine in California and, therefore, is
not authorized to handle controlled substances in California, I will
order
[[Page 42016]]
that Registrant's DEA registration be revoked.
Order
Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No.
BS2811392 issued to Brent E. Silvers, M.D. Further, I hereby deny any
pending application of Brent E. Silvers, M.D. to renew or modify this
registration, as well as any pending application of Brent E. Silvers,
M.D. for registration in California. This Order is effective September
16, 2019.
Dated: August 2, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019-17622 Filed 8-15-19; 8:45 am]
BILLING CODE 4410-09-P